Investor Relations

Upcoming Events

30Jan

2025

Fourth Quarter & Full Year 2024 Results

Fourth quarter and full year 2024 results will be reviewed by management during a live audio webcast with the financial community on January 30, 2025. The presentation will be followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EST)

Quarterly Results

Discover more

24Apr

2025

First Quarter 2025

First quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on April 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly Results

30Apr

2025

Annual General Meeting 2025

The Sanofi General Meeting will be held on April 30, 2025 at the Palais des Congrès in Paris, Porte Maillot. It will be live video webcasted.

14:30 - 16:30

Annual General Meeting (AGM)

All our events

Press Releases

January 13, 2025

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Read the Press Release

January 9, 2025

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Read the Press Release

December 23, 2024

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Read the Press Release

See more press releases

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.